Literature DB >> 19490427

The PFKFB3 splice variant UBI2K4 is downregulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.

K Zscharnack1, R Kessler, F Bleichert, J P Warnke, K Eschrich.   

Abstract

AIMS: Fructose-2,6-bisphosphate, a key regulator of glycolysis, is synthesized and degraded by four different isozymes of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1-4). The PFKFB3 isozyme is upregulated in several human tumours. Six alternatively spliced variants of PFKFB3 mRNA are known in humans (UBI2K1-6). Here, we studied the role of the PFKFB3 splice variants in human astrocytic gliomas.
METHODS: We analysed the PFKFB3 splice variants in 48 astrocytic gliomas by RT-PCR and real-time PCR. The effect of transient and stable overexpression of the PFKFB3 isoforms was studied in U87 glioblastoma cells by MTT, cell counting, clone formation assay and metabolic measurements.
RESULTS: UBI2K5 and UBI2K6 are the predominant splice variants in rapidly proliferating high-grade astrocytomas while the expression of UBI2K3 and UBI2K4 is mainly restricted to low-grade astrocytomas and nonneoplastic brain tissue. Overexpression of UBI2K5 or UBI2K6 in the U87 glioblastoma cell line enhances the glycolytic flux but does not affect cell growth. In contrast, overexpression of UBI2K4 reduces cell viability and anchorage-independent growth of U87 cells. The UBI2K4 mRNA level is downregulated in astrocytic gliomas with increasing malignancy grade. Moreover, the UBI2K4 mRNA level correlates with growth rate of several human cancer cell lines derived from different tissue types.
CONCLUSIONS: Our results demonstrate that the splice variant UBI2K4 impedes the tumour cell growth and might serve as a tumour suppressor in astrocytic tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19490427     DOI: 10.1111/j.1365-2990.2009.01027.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

Review 1.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 2.  Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.

Authors:  Oleksandr H Minchenko; Katsuya Tsuchihara; Dmytro O Minchenko; Andreas Bikfalvi; Hiroyasu Esumi
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 3.  Roles of PFKFB3 in cancer.

Authors:  Linlin Shi; Hongming Pan; Zhen Liu; Jiansheng Xie; Weidong Han
Journal:  Signal Transduct Target Ther       Date:  2017-11-24

Review 4.  Fructose 2,6-Bisphosphate in Cancer Cell Metabolism.

Authors:  Ramon Bartrons; Helga Simon-Molas; Ana Rodríguez-García; Esther Castaño; Àurea Navarro-Sabaté; Anna Manzano; Ubaldo E Martinez-Outschoorn
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

Review 5.  Canonical and Non-Canonical Roles of PFKFB3 in Brain Tumors.

Authors:  Reinier Alvarez; Debjani Mandal; Prashant Chittiboina
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

6.  The future role of personalized medicine in the treatment of glioblastoma multiforme.

Authors:  Jing Li; Chunhui Di; Austin K Mattox; Linda Wu; D Cory Adamson
Journal:  Pharmgenomics Pers Med       Date:  2010-08-19

7.  Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma.

Authors:  Jun Li; Shiqiang Zhang; Dingzhun Liao; Qian Zhang; Chujie Chen; Xiangwei Yang; Donggen Jiang; Jun Pang
Journal:  BMC Cancer       Date:  2022-01-20       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.